TY - JOUR T1 - Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases. AU - Sun,Li-Jing, AU - Shan,Jian-Ping, AU - Cui,Ruo-Lan, AU - Yuan,Wei-Jie, AU - Jiang,Geng-Ru, Y1 - 2017/03/10/ PY - 2016/10/27/received PY - 2017/03/04/accepted PY - 2017/3/12/pubmed PY - 2018/3/22/medline PY - 2017/3/12/entrez KW - ACEI KW - ARB KW - HBV-associated glomerulonephritis KW - Lamivudine KW - Therapeutic efficacy SP - 1049 EP - 1056 JF - International urology and nephrology JO - Int Urol Nephrol VL - 49 IS - 6 N2 - PURPOSE: The treatment of HBV-associated glomerulonephritis (HBV-GN) is still a challenge in clinical practice now. The objective of this study was to report the pathological characteristics of HBV-GN presenting with mild to moderate proteinuria and to evaluate the therapeutic efficacy of lamivudine (LAM) in combination with angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) as compared to ACEI/ARB monotherapy. METHODS: We conducted a retrospective observational study in HBV-GN patients between 2005 and 2014. The patients were classified into two groups: Group 1 included patients treated with LAM plus ACEI/ARB (n = 20), and group 2, patients treated with ACEI/ARB alone (n = 18). Their clinical and pathological characteristics were collected; we analyzed the therapeutic responses and assessed the correlation between renal and liver pathologies. RESULTS: Our results showed that the most common type of HBV-GN was IgA nephropathy. LAM plus ACEI/ARB therapy was better in reducing 24-h urinary protein excretion, alanine aminotransferase, and aspartate aminotransferase levels, while maintaining the level of kidney function. The proportion of patients who achieved remission (CR + PR) was higher in the LAM plus ACEI/ARB group than in the ACEI/ARB monotherapy group (χ 2 = 5.371, P = 0.035). CONCLUSION: In the HBV-GN patients with mild to moderate proteinuria, LAM plus ACEI/ARB not only improved liver function but also better reduced 24-h proteinuria. SN - 1573-2584 UR - https://www.unboundmedicine.com/medline/citation/28283858/Combination_therapy_with_lamivudine_and_angiotensin_converting_enzyme_inhibitor/angiotensin_receptor_blocker_for_hepatitis_B_virus_associated_glomerulonephritis_with_mild_to_moderate_proteinuria:_a_clinical_review_of_38_cases_ L2 - https://doi.org/10.1007/s11255-017-1563-5 DB - PRIME DP - Unbound Medicine ER -